Etidronate disodium in the treatment of Paget's disease of bone.
S M Krane
Index: Ann. Intern. Med. 96(5) , 619-25, (1982)
Full Text: HTML
Abstract
Control of Paget's disease of bone has been possible through treatment with agents that decrease bone resorption; calcitonins, diphosphonates, and mithramycin. The pagetic lesion is not, however, cured. Etidronate disodium is one of the diphosphonates. The clinical improvement attained with this drug has to be set against adverse effects, of which pain is probably the most bothersome in practice. Clinical remission can last as long as 2 years after treatment is stopped.
Related Compounds
Related Articles:
Effects of various squalene epoxides on coenzyme Q and cholesterol synthesis.
2014-07-01
[Biochim. Biophys. Acta 1841(7) , 977-86, (2014)]
2014-12-01
[Lancet Oncol. 15(13) , 1460-8, (2014)]
2014-10-24
[J. Chromatogr. A. 1365 , 131-9, (2014)]
Risk of atypical femoral fracture during and after bisphosphonate use.
2015-02-01
[Acta Orthop. 86(1) , 100-7, (2015)]
The role of risedronate in osteopenia in Crohn's disease.
2015-01-01
[Gut 64(1) , 185, (2015)]